德国初级转诊机构两年常规应用七基因 panel 检测甲状腺细针穿刺标本的评估
这项前瞻性多中心研究在德国64名医生的常规初级转诊环境中,对564份甲状腺细针穿刺(FNA)涂片进行七基因 panel 检测,并与手术组织学及超过1年的随访比较。结果显示 BRAF 和 RET/PTC 突变与癌高度相关,但 RAS 和 PAX8/PPARG 突变阳性预测值有限,当前七基因 panel 未能改善术前诊断。
要点
- BRAF 和 RET/PTC 突变分别与98%和100%的样本癌相关。
- RAS 和 PAX8/PPARG 突变分别与31%和0%的样本癌相关。
- 当前七基因 panel 在常规初级转诊环境中未改善甲状腺 FNA 的术前诊断。
核心结论
- 数据提示在常规初级转诊环境中应用当前七基因 panel 并未改善甲状腺 FNA 的术前诊断。
- RAS 突变在甲状腺肿瘤中的诊断相关性需进一步研究,更全面的包含更多癌症特异性突变的 panel 可能改善术前诊断。
研究设计与样本
- 前瞻性多中心研究,分析来自德国内分泌和核医学诊所的 FNA 标本。
- 从64名医生获取的564份常规风干 FNA 涂片提取 RNA 和 DNA,由一名经验丰富的细胞病理学家进行细胞学分级。
- 采用定量聚合酶链反应检测 PAX8/PPARG 和 RET/PTC 重排,采用焦磷酸测序检测 BRAF 和 RAS 突变。
- 分子数据与组织学和超过1年的随访比较,322/348例手术患者和33/74例随访患者有可用数据。
- 组织学结果来自对分子检测结果不知情的当地常规病理学家。
主要发现
- BRAF 和 RET/PTC 突变分别与98%和100%的样本癌相关。
- RAS 和 PAX8/PPARG 突变分别与31%和0%的样本癌相关。
- 在意义未明的异型性/意义未明的滤泡性病变和滤泡性肿瘤/可疑滤泡性肿瘤类别中,分子检测识别了36%的癌,恶性率分别为15%和17%。
- 在意义未明的异型性/意义未明的滤泡性病变和滤泡性肿瘤/可疑滤泡性肿瘤类别中,阳性预测值分别为41%和36%,诊断潜力有限。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Major differences with respect to the diagnostic performance of a "ruling in" approach in the presurgical diagnosis of indeterminate thyroid fine-needle aspirations (FNAs) have been reported. Therefore, the aim of this prospective multicenter study was to investigate the specific diagnostic impact of mutation testing using a seven-gene panel in a routine primary referral setting analyzing FNAs from endocrinology and nuclear medicine practices in Germany. METHODS: RNA and DNA was extracted from 564 routine air-dried FNA smears obtained from 64 physicians and cytologically graded by one experienced cytopathologist. PAX8/PPARG and RET/PTC rearrangements were detected by quantitative polymerase chain reaction, while BRAF and RAS mutations were detected by pyrosequencing. Molecular data were compared to histology and follow-up >1 year, which were available for 322/348 patients undergoing surgery and 33/74 patients having follow-up. Histology results were obtained from the local routine pathologists who were blinded to the molecular test results. RESULTS: BRAF and RET/PTC mutations were associated with carcinoma in 98% and 100% of samples, respectively. RAS and PAX8/PPARG mutations were associated with carcinoma in 31% and 0% of samples, respectively. Thirty-six percent of the carcinomas were identified by molecular testing in the atypia of undetermined significance/follicular lesion of undetermined significance and follicular neoplasm/suspicious for a follicular neoplasm categories, with malignancy rates of 15% and 17%, respectively. Due to a low percentage of RAS mutation-positive carcinomas in combination with a rather high percentage of RAS mutation-positive benign nodules, the positive predictive values of 41% and 36% in the atypia of undetermined significance/follicular lesion of undetermined significance and follicular neoplasm/suspicious for a follicular neoplasm categories offer only limited diagnostic potential. CONCLUSION: In conclusion, the data suggest that the application of the current seven-gene panel in a routine primary referral setting does not improve the presurgical diagnosis of thyroid FNAs. While the diagnostic relevance of RAS mutations in thyroid tumors needs further investigation, more comprehensive mutation panels with more cancer-specific mutations may improve the presurgical diagnosis of thyroid FNAs.
引用
- Eszlinger M, Böhme K, Ullmann M, et al. Evaluation of a Two-Year Routine Application of Molecular Testing of Thyroid Fine-Needle Aspirations Using a Seven-Gene Panel in a Primary Referral Setting in Germany. Thyroid. 2017. PMID: 28071986. doi:10.1089/thy.2016.0445
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。